REPH Recro Pharma Inc.

16.5
+0.25  (+2%)
Previous Close 16.25
Open 16.29
Price To Book -18.97
Market Cap 375,050,726
Shares 22,730,347
Volume 118,182
Short Ratio
Av. Daily Volume 274,848
Stock charts supplied by TradingView

NewsSee all news

  1. Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization

    Recro Capitalizing on Strong and Growing CDMO Business Business Poised to Continue Driving Revenue and Begin Generating Profits Recro Will Continue to Trade on NASDAQ Under Ticker Symbol "REPH" MALVERN, Pa., Nov. 21,

  2. Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies

    Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline Assets Trading of "BXRX" Begins Tomorrow on NASDAQ MALVERN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) --

  3. Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement

    Separation of Baudax Bio as Independent Company Expected to be Completed With Distribution on November 21, 2019 Baudax Bio Common Stock Approved for Listing on the NASDAQ Capital Market MALVERN, Pa., Nov. 13, 2019

  4. Recro Pharma Reports Third Quarter 2019 Financial Results

    CDMO Business Achieves 37% Growth in 2019 Year to Date Revenues; Consolidated Company Achieves Profitability from Operations, Turns Cash Flow Positive and Raises 2019 Revenue Guidance to $98-100 Million FDA Grants

  5. Recro Pharma to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 8, 2019

    MALVERN, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report third quarter financial results on Friday, November 8, 2019.  Recro's management team will host a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

First CRL announced May 24, 2018. Second CRL issued March 22, 2019. Intends to appeal decision.
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery

Latest News

  1. Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization

    Recro Capitalizing on Strong and Growing CDMO Business Business Poised to Continue Driving Revenue and Begin Generating Profits Recro Will Continue to Trade on NASDAQ Under Ticker Symbol "REPH" MALVERN, Pa., Nov. 21,

  2. Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies

    Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline Assets Trading of "BXRX" Begins Tomorrow on NASDAQ MALVERN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) --

  3. Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement

    Separation of Baudax Bio as Independent Company Expected to be Completed With Distribution on November 21, 2019 Baudax Bio Common Stock Approved for Listing on the NASDAQ Capital Market MALVERN, Pa., Nov. 13, 2019

  4. Recro Pharma Reports Third Quarter 2019 Financial Results

    CDMO Business Achieves 37% Growth in 2019 Year to Date Revenues; Consolidated Company Achieves Profitability from Operations, Turns Cash Flow Positive and Raises 2019 Revenue Guidance to $98-100 Million FDA Grants

  5. Recro Pharma to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 8, 2019

    MALVERN, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report third quarter financial results on Friday, November 8, 2019.  Recro's management team will host a

  6. FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application

    Received Positive Response from FDA Regarding IV Meloxicam Formal Dispute Resolution Request Company Remains on Track to Execute Spin Out of Acute Care Business Segment During the Fourth Quarter of 2019 MALVERN,